Keywords: Deuterium, Deuterium
Motivation: Distinguishing Alzheimer’s Disease form other dementias is becoming increasingly important with the development of amyloid-targeting therapies. This requires extensive clinical and paraclinical work-up, often including structural and molecular brain imaging.
Goal(s): To compare deuterium metabolic imaging (DMI) with routinely used clinical imaging technologies for the detection of Alzheimer’s Disease.
Approach: We performed a prospective clinical trial of 5 healthy age-matched controls compared with 10 patients Alzheimer’s dementia.
Results: Deuterium metabolic imaging showed decreased metabolism in temporal and parietal brain regions in patients with Alzheimer’s disease compared with healthy controls. This hypometabolic pattern correlated well with FDG-PET.
Impact: This preliminary study suggests that metabolic imaging in suspected dementia may be performed with DMI. This would allow simultaneous imaging of structural, vascular, and metabolic changes at a cost comparable to FDG-PET.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords